increased solubility = different PK profile? [Dissolution / BCS / IVIVC]

posted by ElMaestro  – Denmark, 2017-06-08 20:45 (2844 d 00:45 ago) – Posting: # 17470
Views: 14,928

Hi Dr_Dan,


❝ O.k., I see I need to add some more information. The idea behind this question is to develop an oral formulation with a less drug load than the reference product but with the same bioavailability in order to decrease non-systemic adverse events.


"To support safety, it should be demonstrated that the systemic exposure is not higher for the test product than for the reference product, i.e. the upper limit of the 90% confidence interval should not exceed the upper bioequivalence acceptance limit 125.00."

Taken from section 3.4 here.

In my experience it is enforced the way it is written and even though 3.4 deals with OIP&scaling the sentence is enforced verbatim even in situations where scaling is not a topic when a 10.3 submission is foreseen even if it isn't an OIP.
Pick the right agency. I can't emphasize it enough. :ok::pirate:
—
Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,409 posts in 4,921 threads, 1,669 registered users;
21 visitors (0 registered, 21 guests [including 2 identified bots]).
Forum time: 20:30 CET (Europe/Vienna)

Facts are meaningless. You could use facts to prove
anything that’s even remotely true!    Homer Simpson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5